Features of the subpopulation composition of dendritic cells in patients with rheumatoid arthritis

Rheumatoid arthritis (RA) is one of the most common rheumatic diseases. Dendritic cells (DCs) as the main antigen-presenting cells play an important role in the pathogenesis of RA. There are two major DC populations: myeloid and plasmacytoid DCs (mDCs and pDCs). B cells as antibody-producing cells also play an important role in the pathogenesis of RA. The probability of achieving low disease activity and clinical and laboratory remission has been proven to be maximal in the very early period of the disease and in the patients who have not been previously prescribed disease-modifying antirheumatic drugs (DMARDs). In this connection, it is necessary to elaborate additional criteria and biomarkers for early RA.

Objective: to investigate the subpopulation composition of DCs in patients with early-stage RA.

Patients and methods. The investigation enrolled 60patients with RA who met the 2010 ACR/EULAR and the 1987ACR criteria. The patients with RA were divided into two groups: 1) 30patients with early RA (the disease duration was not more than 1 year); 2) 30 patients with advanced RA. A control group consisted of 30 patients with osteoarthritis (OA) who met the ACR criteria. All the patients with RA were treated with DMARDs. The patients with early RA had not previously received DMARDs; after being included in the study, they were prescribed methotrexate 15-20 mg/week. The patients with advanced RA took methotrexate 15-25 mg/week (n=24), sulfasalazine 2 g/day (n=5), or leflunomide 20 mg/day (n=1).

At the first stage, the levels of different subpopulations of DCs and B lymphocytes were studied in the patients with early RA before initiation of therapy and in those with advanced RA and in the control persons. At the following stage, the time course of changes was investigated in the subpopulation composition of DCs and B lymphocytes during therapy.

Results and discussion. The subpopulations of peripheral blood DCs in early RA were characterized. A subpopulation of mDCs was shown to dominate in the patients with early RA versus those with advanced RA or osteoarthritis (OA). In addition, the patients with RA showed a high B lymphocyte level. It was noted that there was no significant differences in the level of pDCs between RA and OA patients and there was an inverse relationship between the relative peripheral blood level of pDC and disease activity, which confirms the immunosuppressive role of pDCs in the pathogenesis of RA. The levels of mDCs and B lymphocytes during DMARD therapy were ascertained to significantly decrease to those seen in healthy donors.

Conclusion. Thus, the findings suggest that the number of mDCs and B lymphocytes increases in patients with early RA, unlike those with OA. In addition, the change in the number of mDCs and B cells during therapy is associated with the dynamics of disease activity and may suppose that mDCs are a target for the action of DMARDs.

1. Nasonov EL. Revmatoidnyi artrit [Rheumatoid arthritis]. Moscow: GEOTAR-Media; 2008. P. 290-331.

2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009 Feb 21;373(9664):659-72. doi: 10.1016/S01406736(09)60008-8. Epub 2009 Jan 20.

3. O’Dell JR. Rheumatoid arthritis. In: Arend WP, Armitage JO, Clemmons DR, et al, editors. Goldman's Cecil Medicine. New York: Elsevier; 2012. P. 1681–9.

4. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017 Feb 21;46(2): 183-196. doi: 10.1016/j.immuni.2017.02.006.

5. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol. 2009 Mar;21(2):118-23. doi: 10.1097/BOR.0b013e3283235ac4.

6. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification crite-ria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi: 10.1136/ard.2010.138461.

7. Arnett FC, Edworthy SM, Bloch DA, et al. American Rheumatism Assosiation 1987 revised criteria for the classification of rheumathoid arthritris. Arthritis Rheum. 1988 Mar;31(3):315-24.

8. Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006;8(1):R15.

9. Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood. 2000 Aug 1;96(3): 878-84.

10. Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018 May; 154(1):3-20. doi: 10.1111/imm.12888. Epub 2018 Feb 27.

11. Jongbloed SL, Benson RA, Nickdel MB, et al. Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. JImmunol. 2009 Jan 15;182(2):963-8.

12. Corsiero E, Bombardieri M, Carlotti E, et al. Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs. Ann Rheum Dis. 2016 Oct;75(10):1866-75. doi: 10.1136/annrheumdis-2015-208356. Epub 2015 Dec 9.

13. Pitzalis C, Jones GW, Bombardieri M, Jones SA. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol. 2014 Jul;14(7):447-62. doi: 10.1038/nri3700. Epub 2014 Jun 20.

14. Gerlag DM, Safy M, Maijer KI, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. Ann Rheum Dis. 2019 Feb; 78(2):179-185. doi: 10.1136/annrheumdis-2017-212763. Epub 2018 Dec 1.

15. Kurochkina YuD, Tikhonova MA, Tyrinova TV, et al. Characteristics of dendritic cells in patients with rheumatoid arthritis with different types of drug therapy. Byulleten' sibirskoi meditsiny. 2017;16(4):195-206. (In Russ.).